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Conditional survival and excess mortality after 
high-dose therapy with autologous stem cell 
transplantation for adult refractory or relapsed
Hodgkin lymphoma in Norway 
The prognosis for patients with Hodgkin lymphoma (HL)
under 60-65 years is very good, with 5-year overall survival
(OS) of 88%-95% with modern combined modality thera-
py, even in advanced stages.1 However, in some patients,
the disease will be refractory to or relapse soon after first-
line therapy. For these patients, the prognosis is worse, and
high-dose therapy with autologous stem cell transplanta-
tion (HDT-ASCT) has been shown to be the optimal sal-
vage therapy for patients with chemo-sensitive disease and
without major co-morbidities.2-4 Patients with HL treated
with HDT-ASCT are at increased risk of premature death
compared to the general population,5-7 mainly due to
relapse of their primary disease, but also because of treat-
ment-related complications and late effects.5-9 Survival esti-
mates are traditionally reported from time of HDT-
ASCT.3,4,10 However, the mortality rate decreases over time
from treatment, as most relapses occur within the first few
years. Hence, presenting survival estimates conditioned on
being alive after different periods of time after HDT-ASCT
is more applicable to patients who have already survived
some time after therapy. This population-based study
included the complete unselected cohort of adult
Norwegian patients with HL treated with HDT-ASCT from
1987-2008. We found that 63% were alive after ten years.
The cohort had 17-fold increased mortality compared to
the general population. However, the conditional survival
improved steadily for each additional year, and while still
elevated beyond five years, there was no excess mortality
after ten years. 
VanderWalde et al. examined conditional relative sur-
vival after HDT-ASCT for all hematologic malignancies
(n=2388) treated in a single institution from 1986-2006.7
For HL (n=466), they reported a 5-year relative survival of
59%, with a standardized mortality ratio (SMR) of 29.4.
Conditioned on having survived 1-10 years after HDT-
ASCT, the 5-year survival probability increased to 67%-
91%, and the mortality approached, but did not reach, that
of the general population (SMR=2.7) after ten years. Others
have reported estimates of 10-year OS for 2-year survivors
after HDT-ASCT ranging from 66%-77%.6,8,9 Earlier reports
on relative survival for 2-year survivors ten years after
HDT-ASCT are conflicting, with findings of no excess mor-
tality,5 but also up to 15-fold increased risk compared to the
general population, even after ten years.6 Nevertheless,
conditional survival after HDT-ASCT for HL specifically
has yet to be studied in a population-based national sam-
ple. 
The aims of this population-based multi-center study
were to investigate conditional OS and SMR in a national
cohort of HL-patients treated with HDT-ASCT, and sec-
ondly to analyze cause of death and incidence of second
malignancies.
All patients aged 18 years or over treated with HDT-
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Figure 1. Kaplan-Meier curves showing overall survival after high-dose therapy with autologous stem cell transplantation (HDT-ASCT) for
relapsed/refractory Hodgkin lymphoma for the entire cohort (n=150) (A), and by treatment period (B), time from diagnosis to HDT-ASCT
(C) and disease status at HDT-ASCT (D). Observation time are calculated from time of HDT-ASCT to death or cut off at June 30th 2014. 
P-values are obtained from log rank tests. CR: complete remission; CRu: complete remission unconfirmed; PR: partial remission and SD:
stable disease. 
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ASCT for HL in Norway in the period 1987-2008 were
included. Clinical data collected from patients’ charts were
linked with national registries for information about date
and cause of death (Statistics Norway) and data on second
malignancies (the Cancer Registry of Norway) by using the
11-digit personal identification number given to all
Norwegian citizens. The Cancer Registry of Norway con-
tains information on all new cancers occurring in Norway
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Table 1. Patients’ characteristics and Cox regression analysis.
Univariate Cox-regression Multivariate Cox-regression
n % HR 95 % CI P HR 95 % CI P
Age at diagnosis (years)
Median (range) 31 (10-64)
<25 50 33 % 0.53 0.25-1.15 0.11
25-44 80 53 % 0.69 0.35-1.38 0.30
≥45 20 14 % Ref 
Age at HDT-ASCT (years)
Median (range) 33 (18-65)
<25 34 23 % 0.71 0.33-1.52 0.38 0.54 0.24-1.21 0.13
25-44 87 58 % 0.71 0.38-1.31 0.28 0.84 0.44-1.59 0.58
≥45 29 19 % Ref Ref
Sex
Male 87 58 % 1.03 0.61-1.73 0.92 1.15 0.64-2.05 0.64
Female 63 42 % Ref Ref
Histological subtype
Classical HL 131 87 % 1.39 0.34-5.73 0.65
NLPLH 7 5 % Ref
Missing/not specified 12 8 %
Ann Arbor stage at diagnosis
I 14 9 % 0.93 0.36-2.38 0.87
II 55 37 % 0.77 0.39-1.51 0.44
III 45 30 % 0.88 0.45-1.74 0.72
IV 35 23 % Ref
Missing 1 1 %
High-dose regimen
TBI + HD cyclophosphamide 16 11 % 1.76 1.03-4.37 0.13
BEAM 134 89 % Ref
Primary chemotherapy
ABVD-like 113 75 % 1.41 0.51-3.93 0.51
MOPP-like 15 10 % 2.97 0.65-7.16 0.21
CHOP-like 12 8 % Ref
Other incl. BEACOPP 5 3 %
None/missing 5 3 %
Radiotherapy
Mediastinal 105 70 % 1.12 0.52-2.38 0.77
Other 23 15 % 1.00 0.37-2.66 0.99
None 22 15 %
Treatment period
1987-1995 19 13 % 2.88 1.35-6.15 0.01 8.60 3.24-22.83 <0.01
1996-2002 70 47 % 1.44 0.79-2.63 0.24 1.82 0.94-3.53 0.08
2003-2008 61 40 % Ref Ref
Time from diagnosis to HDT-ASCT
Median months (range) 21 (3-272)
< 3 years 111 74 % 2.44 1.19-4.99 0.01 3.99 1.75-9.11 <0.01
≥ 3 years 39 26 % Ref Ref
Treatment lines before HDT-ASCT
2 123 82 % 1.89 0.86-4.18 0.12
≥ 3 27 18 % Ref
Disease status at HDT-ASCT
PR/SD 107 71 % 1.32 0.70-2.50 0.39 2.72 1.24-5.93 0.01
CR/CRu 36 24 % Ref Ref
Missing 7 5 %
Patients’ characteristics and uni- and multivariate Cox-regression analyses of potential prognostic factors for overall survival after high-dose therapy with autologous stem cell
transplantation (HDT-ASCT) for relapsed/refractory Hodgkin lymphoma (HL) (n=150). HR: Hazard Ratio; CI: confidence intervals; NLPHL: nodular lymphocyte predominant
Hodgkin lymphoma; TBI: total body irradiation; BEAM: BCNU, etoposide, cytarabin and melphalan; ABVD-like: doxorubicin, bleomycin, vinblastine, dacarbazine and dexam-
ethasone and similar regimens; MOPP-like: chlorambucil, vinblastine, procarbazine and prednisolone; CHOP-like: cyclophosphamide, doxorubicin, vincristine and prednisolone
and similar; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisolone; CR: complete remission; CRu: complete remission
unconfirmed; PR: partial remission (n=103); SD: stable disease (n=4).
based on compulsory reporting for all hospitals, laborato-
ries and physicians (98.8% overall completeness).11
Observation time for survival analyses was calculated from
time of HDT-ASCT to death or cut off at 30th June 2014.
Data on second cancer were available only until end of
2011. Details on statistical analysis, methods and treatment
are given in the Online Supplementary Appendix.
In total, 150 patients were included in the cohort (Table
1). With a median observation time from HDT-ASCT of 8.9
years (range 0.02-24.3), the 5-, 10- and 15-year OS were
73% (95%CI: 65%-79%), 63% (95%CI: 54%-70%) and
59% (95%CI: 50%-62%), respectively (Figure 1).
Treatment period 1987-1995 versus 2003-2008 (P<0.01),
time from diagnosis to HDT-ASCT of less than three years
(P<0.01) and not achieving complete remission (CR) before
HDT-ASCT (P=0.01) were associated with poorer survival
in multivariate analysis (Table 1). This is in line with previ-
ous findings among HL patients treated with HDT-
ASCT10,12 and for 2-year survivors  of  HDT-ASCT for all
lymphomas.6 In recent years, methods available for assess-
ing treatment response after induction therapy have
improved. Most of our patients were treated before
positron emission tomography (PET) became widely avail-
able, and biopsies to decide if any residual lesions were bio-
logically active were less frequently performed. Our catego-
rization of disease status is, therefore, not fully comparable
to current PET-based criteria. Age at HDT-ASCT has previ-
ously been described as a predictor for survival after HDT-
ASCT,5-7,10,12 but did not affect the outcomes in our cohort. 
The 1-, 5- and 10-year conditional OS are shown in
Figure 2. The conditional survival increased steadily for
each additional year survived. One-year OS increased from
89% after HDT-ASCT to 95% conditioned on surviving
the first two years after HDT-ASCT, and reached 100%
conditioned on surviving the first eight years. The 5-year
OS conditioned on having survived two, five and ten years
after ASCT-HDT were 80%, 86% and 95%, respectively.
The 10-year OS conditioned on having survived two and
five years was 75% and 82%, respectively.
Standardized mortality ratio for the entire cohort was
16.9 (95%CI: 13.0-22.0). For patients having survived two,
five and ten years after HDT-ASCT, the SMRs decreased to
9.5 (95%CI: 6.6-13.4), 4.8 (95%CI: 2.9-8.0) and 1.6
(95%CI: 0.6-4.3), respectively. There was, thus, no
increased mortality after ten years compared to the general
Norwegian population. While this is consistent with a pre-
vious study,5 others have reported increased mortality even
beyond ten years.6,7
Among deceased patients (n=60), the cause of death was
HL in 36 cases (60% of deaths). Treatment-related mortal-
ity occurred in 3 cases, on days 7, 47 and 147. Second
malignancies (n=9) was the most common non-relapse-
related cause of death (non-Hodgkin lymphoma (n=2),
leukemia/myelodysplastic syndrome (MDS) (n=5), solid
cancers (n=2), confirming previous findings.5-9 The remain-
ing causes of death were heart disease (n=3), sudden death
of unknown cause (n=4), other (n=4), and missing (n=1).
The 10-year cumulative incidence of HL-deaths and deaths
from other causes were 24.6 (95%CI: 18.3%-32.6%) and
16.0 (95%CI: 10.4%-24.1%), respectively (Online
Supplementary Figure S1). A higher relapse-related death
rate of 78% after HDT-ASCT has previously been
reported.7 However, since that study also included other
hematologic malignancies with higher risk of relapse and
poorer survival after HDT-ASCT than HL,13 a higher pro-
portion of relapse-related deaths would be expected com-
pared to our cohort. Studies including only patients alive
and in CR two years after HDT-ASCT, and thus excluding
any relapses occurring in the first two years, report the pro-
portion of relapse-related deaths to approximately 60%.5,8,9
With median observation time of seven years from HDT-
ASCT (9 years for patients alive 31st December 2011), a sec-
ond malignancy was diagnosed in 9 patients (6%) after a
median five years (range 1-13): non-Hodgkin lymphoma
(n=4), acute leukemia/MDS (n=3) and solid cancers (n=2).
Three of these patients had received prior MOPP-like
chemotherapy and 8 had received prior radiotherapy,
including 3 with total body irradiation (TBI). A population-
based Australian study (n=7765) reported a similar 10-year
incidence of second malignancies after HDT-ASCT for any
cancer (5%),14which is lower than reports on HL survivors
specifically after HDT-ASCT.8-10 Some of these studies,
however, had a median follow-up time of over ten years
from HDT-ASCT. We only have information from the
Cancer Registry until the end of 2011, and it is likely that
the number of cases of second malignancies will increase
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Figure 2. Conditional overall survival
after high-dose therapy with autologous
stem cell support (HDT-ASCT) for
Hodgkin lymphoma (calculated using
the life-table method). Curves are given
if 10 or more patients were alive at start
of follow-up year. HDT: high dose thera-
py; OS: overall survival.
Time from high-dose therapy (years)
with longer observation time. This is also indicated by the
fact that, of the 8 deaths registered after 2011, 5 were
caused by second malignancies [NHL (n=1),
leukemia/MDS (n=2) and solid cancer (n=2)]. These were
all diagnosed after the cut off for second malignancies, and
could, therefore, not be included in the analysis on second
malignancies. 
The median observation time for survival analysis of nine
years from HDT-ASCT and 11 years from diagnosis is also
most likely to be too short to estimate the true risk of mor-
tality due to late effects such as cardiovascular disease and
second malignancies, especially for patients who have
received RT.15 To detect any such increased mortality that
might occur 20 years or longer after diagnosis or HDT-
ASCT, the cohort will be observed further. Nevertheless,
the relatively low risk of death from causes other than HL
is encouraging in this heavily treated cohort, but may be
expected due to less toxic treatment during later decades
and improved treatment outcomes both from cancers and
cardiovascular diseases. In addition, increased awareness of
treatment-related morbidity might have led to earlier detec-
tion.
While conditional survival after HDT-ASCT for all hema-
tologic malignancies, including HL, has been investigated in
a large single center study,7 to our knowledge this is the first
report on conditional survival and SMR in a national cohort
of patients with HL specifically. Despite a relatively small
sample size, the major strength of our study is the national
population-based design including all patients with HL
treated with HDT-ASCT in a homogenous population,
with well-characterized data from high-quality national
registries combined with detailed treatment data from each
hospital. 
In conclusion, the majority of patients with
relapsed/refractory HL are cured after HDT-ASCT. The
expected survival rapidly improves after having survived
the first few years. Although survivors are at increased risk
of premature death beyond five years after HDT-ASCT, the
mortality eventually reaches that of the general population
after ten years.
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